Regenxbio (Regenxbio) Total Liabilities : $238.55 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Total Liabilities?

Regenxbio's Total Liabilities for the quarter that ended in Mar. 2024 was $238.55 Mil.

Regenxbio's quarterly Total Liabilities declined from Sep. 2023 ($270.69 Mil) to Dec. 2023 ($262.23 Mil) and declined from Dec. 2023 ($262.23 Mil) to Mar. 2024 ($238.55 Mil).

Regenxbio's annual Total Liabilities declined from Dec. 2021 ($349.61 Mil) to Dec. 2022 ($317.07 Mil) and declined from Dec. 2022 ($317.07 Mil) to Dec. 2023 ($262.23 Mil).

Regenxbio Total Liabilities Historical Data

The historical data trend for Regenxbio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Total Liabilities Chart

Regenxbio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

47.71

330.41

349.61

317.07

262.23

Regenxbio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															282.69	276.60	270.69	262.23	238.55

Regenxbio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regenxbio's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	130.272	+	(82.222	+	49.734
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	262.23

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	573.97	-	311.742
	=	262.23

Regenxbio's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	110.179	+	(80.183	+	48.187
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	238.55

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	629.215	-	390.666
	=	238.55

Regenxbio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regenxbio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenxbio (Regenxbio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RB0:Germany

Address

9804 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.regenxbio.com

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Executives

Kenneth T. Mills	director, officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista	officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola	officer: Chief Medical Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox	director, 10 percent owner	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas	officer: Senior VP, General Counsel	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson	officer: SVP of Technical Operations	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos	officer: Chief Scientific Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo	officer: Chief Medical Officer	C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse	director	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809